CKI-based treatments were tested on six different cancer cell lines (HT-29, SW-480, DLD-1, U-87 MG, U-251 MG and MDA-MB-231) and two non-cancerous cell lines (HEK-293 and HFF), at five doses ranging from 0 to 2 mg/ml (Figure 2B). The gene discussed is CHKA; the disease is cancer.